Corcept Therapeutics

Clinical Sales Specialist (CS) - Columbia East

Columbia, North Carolina, United States

$60,000 – $80,000Compensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical Sales, Medical DevicesIndustries

Requirements

Candidates must possess a Bachelor's degree or equivalent work experience, along with a minimum of 5 years of sales experience, with a preference for prior relationships within the endocrine, specialty therapeutic, hospital, or orphan drug sectors. Applicants are required to maintain a valid driving record in accordance with Corcept's vehicle policy and be authorized to work in the United States.

Responsibilities

The Clinical Sales Specialist will build and develop professional relationships with influential prescribers and thought leaders within their assigned territory, leveraging expertise in the therapeutic disease state and the marketplace to anticipate and manage business opportunities. They will develop and implement customer-specific territory plans, prioritize time and effort to optimize physician coverage, participate in education programs and speaker dinners, and manage territory expenses to support sales and marketing activities.

Skills

Sales
Relationship Building
Therapeutic Disease State
Marketplace Strategy
Territory Planning
Physician Coverage
Education
Speaker Dinners

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Remote Work Options
Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.
Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.
Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
Advancements in drug delivery systems could enhance Corcept's product efficacy.
The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI